ICI 153110 is an orally active phosphodiesterase inhibitor with both inotropic and vasodilating properties, designed for the treatment of congestive cardiac failure.

Administration of ICI 153110 resulted in the death of fourteen animals in both high-dose main test and reversibility groups, due to direct or indirect effects. In a female rat receiving 10 mg/kg/day of ICI 153110, a mild focal arteritis was observed, characterized by mixed cell infiltration and early fibrous tissue formation in the artery's outer layer. Premature deaths of two rats were attributed to complications from intratracheal intubation with a dosing solution at 250 mg/kg/day. Additionally, minimal focal arteritis with medial necrosis and inflammation in both the middle and outer layers of the arteries was detected in two other animals administered doses of 5 and 250 mg/kg/day. ICI 153110, an orally active compound with vasodilating and inotropic effects, is aimed at treating congestive cardiac failure.